Answer
In 19 healthy volunteers, rifampicin 600 mg daily reduced single-dose ponatinib 45 mg AUC by 62% and Cmax by 42%; co-administration should be avoided and alternatives sought unless the benefit outweighs the possible risk of ponatinib underexposure.
Sources for this answer
- Ponatinib Incyte 30 mg film-coated tabletsIncyte Biosciences UK Ltd · emc · SmPC §4.5 Interaction with other medicinal products · Version 3Document updated
Sources checked